极目新闻记者 陈洋洋 据新财富杂志日前报道，西北大学副校长范代娣以440亿元的身家成为陕西省首富。5月13日，极目新闻记者就此事致电西北大学宣传处，工作人员表示，目 前没有关注到该消息，范代娣具体的个人信息可以通过官网了解。 13日上午，记者联系巨子生物基因技术股份有限公司，该公司一客服工作人员表示，并不清楚范代娣成为陕西省首富一事。 范代娣和学生们（图源：西北大学官网） 范代娣个人简历（图源：西北大学官网） 随后，记者登录学校官网查询，公开信息显示，范代娣，女，汉族，1966年1月生，陕西蒲城人，中共党员，研究生学历，工学博士，教授，博士生导师。 现任西北大学党委常委、副校长，化工学院院长。分管国际合作部（国际教育学院）、经营性资产管理有限公司。联系外国语学院、化学与材料科学学院。 1994年，于华东理工大学生物工程系博士毕业后进入西北大学工作。历任西北大学化工学院副院长、院长。2025年4月，任西北大学党委委员、常委、副校 长。 范代娣（资料图） 范代娣与丈夫创办巨子生物 据了解，范代娣与丈夫严建亚于2000年9月创立了巨子生物基因技术股份有限公司。自2019年起，巨子生物成为中国最大的胶原蛋白专业皮肤护 ...

Core Insights - The performance of domestic beauty companies in China is showing significant divergence, with some achieving remarkable growth while others face declines, indicating a reshaping of the market landscape [1][4][42] Group 1: Company Performance - Proya has become the first domestic beauty company to enter the 10 billion yuan club, with a revenue of 10.778 billion yuan, growing by 21.04% [2] - Other companies like Shangmei and Juzi Biological also reported substantial revenue increases of 62.08% and 57.17% respectively, while Shanghai Jahwa experienced a revenue decline of 13.93% [2][3] - Six beauty companies have revenues exceeding 5 billion yuan, suggesting that this threshold will soon become a significant benchmark for the top 10 domestic beauty brands [1] Group 2: Profitability Trends - Juzi Biological leads in profitability with a profit of 2.062 billion yuan, up 42.06%, while Proya's profit reached 1.552 billion yuan, growing by 30% [3] - In contrast, Shanghai Jahwa reported a loss of 833 million yuan, marking a 266.60% decline, highlighting the stark differences in profitability among companies [3][11] Group 3: Market Dynamics - The current market dynamics indicate a shift towards efficacy-driven products, with companies that successfully launched standout products seeing better performance [4][5] - The competition is intensifying, with new entrants emerging and established brands needing to adapt to changing consumer preferences and market trends [7][30] Group 4: R&D and Strategic Focus - Companies are increasingly focusing on R&D, with most reporting a rise in R&D expenditures, indicating a strategic shift towards innovation and efficacy [20][21] - The trend of acquisitions and investments in technology is becoming a key strategy for companies aiming to enhance market share and scale [23][24] Group 5: Emerging Opportunities - The male skincare market is growing rapidly, presenting new opportunities for brands to capture this segment [36] - The aging population is creating demand for products targeting older consumers, which remains largely untapped [39] - As online sales plateau, brands are shifting focus to offline channels, indicating a potential new battleground for market share [40]

【申万化妆品】周观点：聚美丽大会指引美业发展，国际集团在华触底反弹20250511 本周聚美丽大会在上海闭幕，聚焦弱背景下行业发展方向，坚定看好科技美妆、精细化运营、AI助力等方向。 本周新闻回顾：美业盛会聚美丽大会圆满落幕。 在国货崛起的背景下，国际品牌也在逆境成长，25Q1包括雅诗兰黛在内的部分重点海外集团，依靠品牌沉淀与近 年变革成果，迎重点品牌在华增速转正。 美妆供给端，在国货品牌进攻，国际品牌反弹的激烈竞争下，有望带动需求 【申万化妆品】周观点：聚美丽大会指引美业发展，国际集团在华触底反弹20250511 本周聚美丽大会在上海闭幕，聚焦弱背景下行业发展方向，坚定看好科技美妆、精细化运营、AI助力等方向。 在国货崛起的背景下，国际品牌也在逆境成长，25Q1包括雅诗兰黛在内的部分重点海外集团，依靠品牌沉淀与近 年变革成果，迎重点品牌在华增速转正。 美妆供给端，在国货品牌进攻，国际品牌反弹的激烈竞争下，有望带动需求端增长。 本周回顾：上海家化(600315)：2024年营收56.79亿元，同比下滑13.93%；归母净利润亏损8.33亿元，同比下滑 266.60%。 25Q1营收17.04亿元，同比下滑10 ...

Core Insights - The domestic beauty industry in China is expected to undergo a significant restructuring by 2025, with companies showing rapid growth driven by strong single-brand performance and a shift in consumer focus towards verified efficacy rather than just ingredient composition [2][10] Revenue Performance - Proya has become the first domestic beauty company to surpass 10 billion yuan in revenue for 2024, achieving 10.779 billion yuan, maintaining its top position [4] - Shangmei Co. has shown the fastest revenue growth, with a 62.1% increase from 4.191 billion yuan in 2023 to 6.793 billion yuan in 2024, rising from sixth to second place among the sample companies [3][4] - Other notable companies include Betaini with 5.736 billion yuan, Shanghai Jahwa with 5.679 billion yuan, and Juzhibio with 5.54 billion yuan, all showing varying degrees of growth [4] Brand Performance - Shangmei's brand Han Shu generated nearly 5.6 billion yuan in 2024, accounting for 82.3% of the group's total revenue, with a growth rate of 73.7% [5] - Juzhibio's brand Kefu Mei achieved 4.54 billion yuan in revenue, representing 82% of its total revenue, with a growth rate of 62.9% [6] Market Trends - The popularity of hyaluronic acid is declining, while "recombinant collagen" is emerging as a lucrative ingredient, reflecting a shift in consumer preferences towards efficacy-driven skincare [7][9] - The market is witnessing a transition from ingredient-focused to efficacy-focused products, with companies like Proya leveraging this trend to capture market share [10][11] R&D and Investment - There is a growing disparity between revenue growth and R&D investment among companies, with Proya's R&D expenditure at only 1.95% of total revenue, the lowest among the sample companies [12] - In contrast, Juzhibio, despite its rapid revenue growth, has a low R&D investment ratio of 1.9%, indicating a potential risk in long-term sustainability [12] Industry Dynamics - The beauty industry is moving towards a phase where product efficacy and R&D capabilities are becoming critical competitive factors, as opposed to relying solely on marketing [13] - The gap in revenue between leading and mid-tier companies is widening, suggesting a trend towards market consolidation and structural transformation within the industry [13]

以下文章来源于新财富杂志 ，作者陶娟 新财富杂志 . 《新财富》杂志专注以权威评价、深度研究，揭示资本的选择与逻辑，促进市场信息透明，改善资源配置效率。 西北大学新任副校长范代娣，持股市值达443亿元，晋升为新一任陕西首富。 范代娣和丈夫严建亚名下的巨子生物、三角防务两家上市公司，总市值近900亿元，分别处于医药生物和航空航天两大领域。 他们的女儿，29岁的严钰博被严格培养，本科在多伦多大学主修双学位，此后一年拿下加大洛杉矶分校硕士学位。毕业后回家"打工"之余，她还 在两年内考下4门金融证书，晋升为巨子生物董秘、执行董事，但2023年年薪仅为14万元，2024年涨薪至36万元。 与女儿"低"收入相映成趣的是，上市三年，巨子生物募资46亿港元、分红23亿港元，预计范代娣家族可获分红13亿港元。 2025年4月，西北大学上任一位女副校长范代娣。她的持股市值合计超过400亿元，或许是教育体制内身家最高的了。 西北大学为教育部与陕西省政府共建综合性全国重点大学，是国家"双一流"建设高校、国家"211工程"建设院校。 在西北大学官网上，范代娣已正式列席副校长一职。 | | 学校概况 | 机构设置 | 师资队伍 | 合作 ...

一克胶原蛋白，2 0年前进口价高达7 0 0 0元，如今国货品牌创福康却做到了" 2 3年不涨价"—— 这背后是一场技术与良心的较量。 近年来，随着胶原蛋白市场的扩大，消费者的质疑声也随之而来：为什么技术⼀创新，成分⼀ 火，国牌就涨价？背后究竟是研发成本，还是割用户韭菜？ 上海品牌策略创意广告公司世之相与张泉灵共同推出《国货就很好》系列IP，第一期就选择了 2 3 年不涨价的品牌——创福康，《国货就很好·拷问中国胶原蛋白》在今年6 1 8 前正式上线。 片中主持人张泉灵与创福康创始人佟刚"当面交锋"，直面消费者疑问。辛辣的内容使该影片一 经上线就收获了高度关注。 这不禁让人产生思考，"狂飙"的胶原蛋白市场之后，以技术取胜的国货品牌究竟要如何通过科 学传播，实现与消费者的最有效沟通？ 当下的胶原蛋白市场正处于三大关键背景： 第一，在市场方面，重组胶原蛋白带动了整体市场发展，胶原蛋白市场正在"第二次爆发"前 夜。 根据弗若斯特沙利文数据，预计到2 0 2 6年，基于胶原蛋白的皮肤专业护理产品的市场份额将 超过透明质酸；到2 0 2 7年，中国胶原蛋白的整体市场规模将达到1 7 3 8亿元。 第二，在科技方面，多个 ...

Group 1 - The core issue involves the investigation of Jiang Wei, a major shareholder and actual controller of Haohai Biological Technology, by the China Securities Regulatory Commission for suspected insider trading [1] - The investigation pertains solely to Jiang Wei as an individual and does not involve the company's stock or daily operations, indicating no significant impact on the company's regular business activities [2] Group 2 - On May 7, Haohai Biological Technology's stock closed at 53.17 yuan per share, down 0.21%, with a market capitalization of 12.4 billion yuan [3] - The company recently announced a stock buyback, having repurchased approximately 1.49 million A-shares, accounting for 0.64% of the total share capital, with a total transaction amount of about 85.94 million yuan [3] - For the fiscal year 2024, Haohai Biological Technology reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, a year-on-year increase of 1.04%, indicating stagnation in growth [3] - The overall gross margin decreased from 70.46% to 69.89%, despite the increasing revenue share from high-margin hyaluronic acid products, due to significant price declines in other products [3] Group 3 - In Q1 2025, Haohai Biological Technology reported total revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit attributable to shareholders of 90.31 million yuan, down 7.41% [4] - The decline in performance reflects intense competition in the hyaluronic acid and medical aesthetics market, with emerging alternative materials reshaping the landscape [4] - Research indicates that recombinant collagen may replicate the success of hyaluronic acid, supported by continuous improvements in supply chain policies and technological breakthroughs [4]

历经二十一载岁月沉淀，新财富金牌董秘评选已成为中国资本市场极具权威性与公信力的标杆评选，不仅见证 了中国资本市场蓬勃发展的壮阔征程，更以专业视角镌刻下时代变革的深刻印记。金牌董秘群体凭借卓越的专 业素养与创新实践能力，持续优化上市公司治理、深化投资者关系管理，已然成为推动中国资本市场向高质量 发展迈进的一股重要力量。 值此新财富董秘评选二十一周年之际，诚邀历届金牌董秘，分享企业战略、发展历程与职业经验，以实战洞见 解构资本风云，共探行业发展逻辑。 0 1 来自合成生物"第一股"的金牌董秘唐梦华 唐梦华女士现任山西锦波生物医药股份有限公司董事、副总经理兼董事会秘书。自2019年加入公司以 来，她深度参与了公司运营管理与合规体系建设，并主导完成了锦波生物的上市工作——这一里程碑 使锦波生物成为中国首家以"重组人源化胶原蛋白"为核心的A股上市公司。2023年7月20日，公司在 北京证券交易所成功上市，为我国中小企业实现原创性成果产业化提供了范本，也成为北交所推 动"硬科技"企业发展的典型案例。 "好公司"要从创新中来，到创新中去 公司简介 锦波生物成立于2008年，总部位于山西太原，是国家级专精特新"小巨人"企业， ...

美护大年 - 年报季报总结 20250505 摘要 • 美护行业整体渗透率提升，价格上行，增长性强于传统食品饮料行业，引 领新消费趋势。投资策略应聚焦具备持续推新能力或积极变化的公司，如 瑞晨、登康、景波等，以及稳健高增长标的和边际改善公司。 • 国产品牌在美护市场迅速崛起，对外资品牌形成替代，尤其日韩品牌下滑 明显。个护板块表现优于医美和化妆品板块，板块内部公司业绩分化显著， 总量数据代表性下降。 • 个护细分赛道 2024 年营收增长 19%，净利润增长 25%。2025 年一季度 收入增长 29%，利润增长 13%，受益于产品创新和抖音渠道带动。毛利 率提升但销售费用率也上升，毛销差小幅收窄。 • 医美板块 2024 年营收增长 16%，净利润增长 22%。2025 年一季度收入 和利润基本持平，板块内部分化明显，重组胶原蛋白针剂龙头锦波生物高 速增长，其他公司短期承压。 • 化妆品行业 2024 年营收增长 11%，净利润下滑 9%（剔除异常值后增长 11%）。线上流量成本上升及部分公司拖累业绩，但巨子生物、毛戈平等 表现优异。珀莱雅通过优化费用投放实现利润快速增长。 Q&A 2024 年和 2025 ...

Core Viewpoints - The report highlights a collective decline in the A-share market indices, with the Shanghai Composite Index down by 0.05% to 3286.65 points, and the Shenzhen Component Index also down by 0.05% [1][6] - The report notes a significant increase in the inbound tourism market in China, with an expected daily average of 2.15 million inbound and outbound travelers during the upcoming "May Day" holiday, representing a year-on-year growth of 27% [2][7] - The report emphasizes the strong performance of Marubi Biotechnology (丸美生物), with a 33.44% year-on-year increase in revenue for 2024, reaching 2.97 billion yuan, and a net profit of 342 million yuan, up 31.69% [8][12] Market Performance - The A-share market saw a total trading volume of 1.02 trillion yuan, with sectors such as beauty care, machinery, and media leading the gains, while public utilities, oil and petrochemicals, and coal sectors lagged [1][6] - The report indicates that the online sales channel for Marubi achieved a revenue of 2.54 billion yuan in 2024, a year-on-year increase of 35.77%, accounting for 85.61% of total revenue [9][12] Company Analysis - Marubi's main brand generated 2.06 billion yuan in revenue, representing a 31.69% increase, while its second brand, PL, achieved 905 million yuan, up 40.72% [9][12] - The gross margin for Marubi improved to 73.70% in 2024 and 76.05% in Q1 2025, reflecting a year-on-year increase of 3.01 percentage points and 1.45 percentage points, respectively [10][12] - The company is transitioning from a traditional cosmetics firm to a biotechnology cosmetics company, focusing on key technologies and core raw material research, particularly in recombinant collagen technology [11][12] Profit Forecast and Investment Recommendations - The report adjusts profit forecasts for Marubi, estimating net profits of 411 million yuan, 476 million yuan, and 537 million yuan for 2025-2027, with year-on-year growth rates of 20.40%, 15.75%, and 12.69% respectively [12]